Drug name - Invega Sustenna

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906 JANSSEN PHARMS Dosing regimen associated with long acting injectable paliperidone esters Jan, 2031

(8 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Treatment: Treatment of schizophrenia; treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loading doses of paliperidone palmitate followed by maintenance dose(s); dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
39MG/0.25ML (39MG/0.25ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
78MG/0.5ML (78MG/0.5ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
117MG/0.75ML (117MG/0.75ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
156MG/ML (156MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
234MG/1.5ML (156MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

availability in other generic markets.

Click on the highlighted region to filter.